The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 18-21

  Bell, Damon A ^a,b,c   Edwards, Glenn ^a   Hooper, Amanda J ^b,c,d   McMahon, Jenny ^a   van Bockxmeer, Frank M ^b,d   Watts, Gerald F ^b,c   Burnett, John R ^b,c  

^a Department of Clinical Biochemistry St John of God Pathology ^*  (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Community laboratory; Detection; Expert computer system; Familial hypercholesterolaemia

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY PROGRAM; COMPUTER SYSTEM; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXPERT SYSTEM; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; INCIDENTAL FINDING; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VASCULAR DISEASE; HYPERLIPOPROTEINEMIA TYPE II; LABORATORY DIAGNOSIS; MIDDLE AGED;

CLINICAL LABORATORY SERVICES; EXPERT SYSTEMS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84934989104     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.06.004     Document Type: Article

References (31)

1. Watts G.F., Sullivan D.R., Poplawski N., et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011, 12:221-231.
2. Bender R., Bell D.A., Hooper A.J., et al. Screening for familial hypercholesterolaemia. Pathology 2012, 44:122-128.
3. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490.
4. Watts G.F., Gidding S., Wierzbicki A.S., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014, 171:309-325.
5. Bell D.A., Hooper A.J., Bender R., et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem 2012, 49:534-537.
6. Bell D.A., Bender R., Hooper A.J., et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clin Chim Acta 2013, 422:21-25.
7. Bell D.A., Hooper A.J., Edwards G., Southwell L., et al. Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis 2014, 234:469-472.
8. Bell D.A., Garton-Smith J., Vickery A., et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ 2014, 23:309-313.
9. Vickery A.W., Bell D., Garton-Smith J., Kirke A.B., Pang J., Watts G.F. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. Heart Lung Circ 2014, 23:1158-1164.
10. Barlow I.M. Do interpretative comments influence patient management and do our users approve of the laboratory 'adding on' requests? A follow-up General Practitioner and Nurse Practitioner survey. Ann Clin Biochem 2009, 46:85-86.
11. Barlow I.M. Are biochemistry interpretative comments helpful? Results of a general practitioner and nurse practitioner survey. Ann Clin Biochem 2008, 45:88-90.
12. Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012, 5:354-359.
13. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012, 97:3956-3964.
14. Bell D.A., Pang J., Burrows S., Bates T., et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis 2015, 293:93-100.
15. World Health Organization Familial Hypercholesterolaemia (FH): Report of a Second WHO Consultation 1999, [Geneva].
16. Weng S.F., Kai J., Neil H.A., Humphries S.E., Qureshi N. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015, 238:336-343.
17. Kilpatrick E.S., Freedman D.B. A national survey of interpretative reporting in the UK. Ann Clin Biochem 2011, 48:317-320.
18. Edwards G.A. Expert systems for clinical pathology reporting. Clin Biochem Rev 2008, 29(Suppl. 1):S105-S109.
19. Edwards G., Kang B.H., Preston P., Compton P. Prudent expert systems with credentials: managing the expertise of decision support systems. Int J Biomed Comput 1995, 40:125-132.
20. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
21. Heart Protection Study Collaborative Group The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005, 3:6.
22. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
23. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
24. Wiegman A., Gidding S.S., Watts G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015, (May, Epub ahead of print).
25. NICE Clinical guideline 71: identification and management of familial hypercholesterolaemia 2008, [London].
26. Humphries S.E., Hadfield G. Identifying patients with familial hypercholesterolaemia in primary care. Heart 2008, 94:695-696.
27. Qureshi N., Humphries S.E., Seed M., Rowlands P., Minhas R. Identification and management of familial hypercholesterolaemia: what does it mean to primary care?. Br J Gen Pract 2009, 59:773-776.
28. Kirke A., Watts G.F., Emery J. Detecting familial hypercholesterolaemia in general practice. Aust Fam Physician 2012, 41:965-968.
29. Civeira F., Ros E., Jarauta E., et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008, 102:1187-1193. [1193 e1181].
30. Damgaard D., Larsen M.L., Nissen P.H., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005, 180:155-160.
31. Gray J., Jaiyeola A., Whiting M., Modell M., Wierzbicki A.S. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart 2008, 94:754-758.